Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FFNP PET/MRI in CAH and Grade 1 Endometrial Cancer
NCT05483023Phase 2Withdrawn
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Feb 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of fluorofuranylnorprogesterone in endometrial cancer (EC), Complex atypical hyperplasia (CAH), sponsored by UNC Lineberger Comprehensive Cancer Center. Planned start Feb 2024; status: withdrawn.
02
Drugs
fluorofuranylnorprogesterone
03
Conditions
endometrial cancer (EC)Complex atypical hyperplasia (CAH)
Beyond the preview
Go deeper on NCT05483023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05483023.